Literature DB >> 32270660

[Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area].

Z P Qian1, X Mei2, Y Y Zhang1, Y Zou1, Z G Zhang1, H Zhu1, H Y Guo1, Y Liu1, Y Ling3, X Y Zhang4, J F Wang1, H Z Lu5.   

Abstract

Objective: To summarize the clinical characteristics and liver biochemical parameters of 324 cases admitted with novel coronavirus pneumonia in Shanghai area.
Methods: Clinical data and baseline liver biochemical parameters of 324 cases with novel coronavirus pneumonia admitted to the Shanghai Public Health Clinical Center from January 20, 2020 to February 24, 2020 were retrospectively analyzed. Patients were divided into two groups based on the status of illness: mild type (mild and typical) and severe type (severe and critical).The differences in clinical data and baseline liver biochemical parameters of the two groups were described and compared. The t-test and Wilcoxon rank-sum test were used for measurement data. The enumeration data were expressed by frequency and rate, and chi-square test was used.
Results: Of the 324 cases with novel coronavirus pneumonia, 26 were severe cases (8%), with median onset of 5 days, 20 cases were HBsAg positive (6.2%), and 70 cases (21.6%) with fatty liver, diagnosed with X-ray computed tomography. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT), total bilirubin (TBil), albumin(ALB) and international normalized ratio (INR) of 324 cases at baseline were 27.86 ± 20.02 U/L, 29.33 ± 21.02 U/L, 59.93 ± 18.96 U / L, 39.00 ± 54.44 U/L, 9.46 ± 4.58 μmol / L, 40.64 ± 4.13 g / L and 1.02 ± 0.10. Of which, ALT was > than the upper limit of normal (> ULN), accounting for 15.7% (51/324). ALT and AST > ULN, accounting for 10.5% (34/324). ALP > ULN, accounting for 1.2% (4/324). ALP and GGT > ULN, accounting for 0.9% (3/324). INR > ULN was lowest, accounting for 0.6% (2/324). There were no statistically significant differences (P > 0.05) in ALT [(21.5 vs. 26) U / L, P = 0.093], ALP [(57 vs.59) U/L, P = 0.674], and GGT [(24 vs.28) U/L, P = 0.101] between the severe group and the mild group. There were statistically significant differences in AST (23 U/L vs. 34 U/L, P < 0.01), TBil (10.75 vs. 8.05 μmol / L, P < 0.01), ALB (35.79 ± 4.75 vs. 41.07 ± 3.80 g/L, P < 0.01), and INR (1.00 vs. 1.04, P < 0.01).
Conclusion: The baseline liver biochemical parameters of 324 cases with novel coronavirus pneumonia in Shanghai area was comparatively lower and the liverinjury degree was mild, and the bile duct cell damage was rare.

Entities:  

Keywords:  Biochemistry; COVID-19; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32270660     DOI: 10.3760/cma.j.cn501113-20200229-00076

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  15 in total

1.  Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review.

Authors:  Szilárd Váncsa; Péter Jeno Hegyi; Noémi Zádori; Lajos Szakó; Nóra Vörhendi; Klementina Ocskay; Mária Földi; Fanni Dembrovszky; Zsuzsa Réka Dömötör; Kristóf Jánosi; Zoltán Rakonczay; Petra Hartmann; Tamara Horváth; Bálint Erőss; Szabolcs Kiss; Zsolt Szakács; Dávid Németh; Péter Hegyi; Gabriella Pár
Journal:  Front Med (Lausanne)       Date:  2020-11-13

Review 2.  COVID-19 in normal, diseased and transplanted liver.

Authors:  Alessandro Signorello; Ilaria Lenci; Martina Milana; Giuseppe Grassi; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

3.  Model of End-Stage Liver Disease (MELD) Score as a Predictor of In-Hospital Mortality in Patients with COVID-19: A Novel Approach to a Classic Scoring System.

Authors:  Peter M Stawinski; Karolina N Dziadkowiec; Baher Al-Abbasi; Laura Suarez; Larnelle Simms; Nakeya Dewaswala; Pedro Torres; Ayat Al Rubaye; Jesus Pino; Akiva Marcus
Journal:  Cureus       Date:  2021-05-22

4.  Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis.

Authors:  Panagiotis Paliogiannis; Angelo Zinellu
Journal:  Liver Int       Date:  2020-05-22       Impact factor: 8.754

Review 5.  Hepatic complications of COVID-19 and its treatment.

Authors:  Dandan Tian; Qing Ye
Journal:  J Med Virol       Date:  2020-06-12       Impact factor: 20.693

Review 6.  Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis.

Authors:  Tatyana Kushner; John Cafardi
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-05-21

7.  Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis.

Authors:  Yanyan Wu; Hongyu Li; Xiaozhong Guo; Eric M Yoshida; Nahum Mendez-Sanchez; Giovanni Battista Levi Sandri; Rolf Teschke; Fernando Gomes Romeiro; Akash Shukla; Xingshun Qi
Journal:  Hepatol Int       Date:  2020-07-24       Impact factor: 6.047

8.  Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.

Authors:  Anand V Kulkarni; Pramod Kumar; Harsh Vardhan Tevethia; Madhumita Premkumar; Juan Pablo Arab; Roberto Candia; Rupjyoti Talukdar; Mithun Sharma; Xiaolong Qi; Padaki Nagaraja Rao; Duvvuru Nageshwar Reddy
Journal:  Aliment Pharmacol Ther       Date:  2020-07-08       Impact factor: 9.524

Review 9.  Positive association between severity of COVID-19 infection and liver damage: a systematic review and meta-analysis.

Authors:  Hajar Shokri Afra; Nasrin Amiri-Dashatan; Fatemeh Ghorbani; Iradj Maleki; Mostafa Rezaei-Tavirani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

10.  Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection.

Authors:  Jiaye Liu; Tingyan Wang; Qingxian Cai; Liqin Sun; Deliang Huang; Guangde Zhou; Qing He; Fu-Sheng Wang; Lei Liu; Jun Chen
Journal:  Hepatol Res       Date:  2020-08-29       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.